Medication-related osteonecrosis of the jaw (MRONJ) is primarily an adverse side effect of
denosumab or bisphosphonates (particularly when used at high doses to prevent skeletal …

Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of bone-
modifying agents and inhibits angiogenesis agents. Although the pathogenesis of MRONJ is …

Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be
exclusively associated with bisphosphonates, has been implicated in recent reports with …

The aim was to evaluate the knowledge about bisphosphonate-related osteonecrosis of the
jaws (BRONJ). A bibliographic search in Medline, PubMed and the Cochrane Register of …

Osteoradionecrosis is one of the most serious oral complications of head and neck cancer
treatment. It is a severe delayed radiation-induced injury, characterized by bone tissue …

Osteonecrosis of the jaw (ONJ) is an uncommon condition noted to occur in patients who are
receiving osteoclast-targeted antiresorptive therapy. The incidence of ONJ in patients taking …

Purpose To date, no ideal strategy has been established for treating or preventing
medication-related osteonecrosis of the jaw (MRONJ). The aim of the present work was to …

PURPOSE: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a well-recognized
pathologic entity that is challenging and difficult to manage. Recent literature contains …

Bisphosphonate-associated osteonecrosis (BON) is a complication that almost exclusively
affects the jaw bones. The clinical presentation of BON often mimics that of other conditions …

INTRODUCTION: Bisphosphonates are used to reduce skeletal related events in patients
with bone consuming diseases such as osteoporosis and bone metastases. However …